Abstract | PURPOSE: DESIGN: Retrospective case study. METHODS: RESULTS: The mean best-corrected visual acuity (BCVA) level was 0.25 at baseline and 0.31, 0.39, 0.44, 0.44, and 0.45 at 1, 3, 6, 9, and 12 months after treatment, respectively. A significant (P< .01) improvement in the mean BCVA was observed at 3, 6, 9, and 12 months after combined therapy. At 12 months, the mean improvement in BCVA from baseline was 2.69 lines; the BCVA improved in 15 eyes (51.7%) by 3 lines or more, was stable in 13 eyes (44.8%), and decreased in 1 eye (3%) because of a massive subretinal hemorrhage 7 months after the first treatment. Eighteen eyes (62%) required 1 combined treatment during follow-up. Polypoidal lesions recurred in 6 eyes (21%). An abnormal branching vascular network persisted in all eyes. The mean number of treatments with combined therapy averaged 1.59. No complications, including endophthalmitis, uveitis, or ocular hypertension, developed. CONCLUSIONS:
|
Authors | Taku Sato, Shoji Kishi, Hidetaka Matsumoto, Ryo Mukai |
Journal | American journal of ophthalmology
(Am J Ophthalmol)
Vol. 149
Issue 6
Pg. 947-954.e1
(Jun 2010)
ISSN: 1879-1891 [Electronic] United States |
PMID | 20346441
(Publication Type: Journal Article)
|
Copyright | Copyright 2010 Elsevier Inc. All rights reserved. |
Chemical References |
- Angiogenesis Inhibitors
- Antibodies, Monoclonal
- Antibodies, Monoclonal, Humanized
- Photosensitizing Agents
- Porphyrins
- Vascular Endothelial Growth Factor A
- Verteporfin
- Bevacizumab
|
Topics |
- Aged
- Aged, 80 and over
- Angiogenesis Inhibitors
(therapeutic use)
- Antibodies, Monoclonal
(therapeutic use)
- Antibodies, Monoclonal, Humanized
- Bevacizumab
- Choroid
(blood supply)
- Choroid Diseases
(diagnosis, drug therapy, physiopathology)
- Combined Modality Therapy
- Female
- Fluorescein Angiography
- Humans
- Injections
- Male
- Middle Aged
- Peripheral Vascular Diseases
(diagnosis, drug therapy, physiopathology)
- Photochemotherapy
- Photosensitizing Agents
(therapeutic use)
- Porphyrins
(therapeutic use)
- Retreatment
- Retrospective Studies
- Tomography, Optical Coherence
- Treatment Outcome
- Vascular Endothelial Growth Factor A
(antagonists & inhibitors)
- Verteporfin
- Visual Acuity
(physiology)
- Vitreous Body
|